Your browser doesn't support javascript.
loading
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Artibani, Mara; Masuda, Kenta; Hu, Zhiyuan; Rauher, Pascal C; Mallett, Garry; Wietek, Nina; Morotti, Matteo; Chong, Kay; KaramiNejadRanjbar, Mohammad; Zois, Christos E; Dhar, Sunanda; El-Sahhar, Salma; Campo, Leticia; Blagden, Sarah P; Damato, Stephen; Pathiraja, Pubudu N; Nicum, Shibani; Gleeson, Fergus; Laios, Alexandros; Alsaadi, Abdulkhaliq; Santana Gonzalez, Laura; Motohara, Takeshi; Albukhari, Ashwag; Lu, Zhen; Bast, Robert C; Harris, Adrian L; Ejsing, Christer S; Klemm, Robin W; Yau, Christopher; Sauka-Spengler, Tatjana; Ahmed, Ahmed Ashour.
Afiliación
  • Artibani M; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Masuda K; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Hu Z; Gene Regulatory Networks in Development and Disease Laboratory, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • Rauher PC; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Mallett G; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Wietek N; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Morotti M; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Chong K; Department of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
  • KaramiNejadRanjbar M; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Zois CE; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Dhar S; Gene Regulatory Networks in Development and Disease Laboratory, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • El-Sahhar S; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Campo L; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Blagden SP; Department of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
  • Damato S; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Pathiraja PN; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Nicum S; Department of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
  • Gleeson F; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Laios A; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Alsaadi A; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Santana Gonzalez L; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Motohara T; Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • Albukhari A; Department of Histopathology, Oxford University Hospitals, Oxford, United Kingdom.
  • Lu Z; Ovarian Cancer Cell Laboratory, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, and.
  • Bast RC; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.
  • Harris AL; Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • Ejsing CS; Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
  • Klemm RW; Department of Histopathology, Oxford University Hospitals, Oxford, United Kingdom.
  • Yau C; Department of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
  • Sauka-Spengler T; Department of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
  • Ahmed AA; Department of Radiology, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
JCI Insight ; 6(11)2021 06 08.
Article en En | MEDLINE | ID: mdl-33945502
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Neoplásicas / Adipocitos / Neoplasia Residual / Transición Epitelial-Mesenquimal / Carcinoma Epitelial de Ovario Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: JCI Insight Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Neoplásicas / Adipocitos / Neoplasia Residual / Transición Epitelial-Mesenquimal / Carcinoma Epitelial de Ovario Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: JCI Insight Año: 2021 Tipo del documento: Article